(R)-1-(3,5-Difluorophenyl)ethanamine
≥95%
- Product Code: 113446
CAS:
771465-40-8
| Molecular Weight: | 157.16 g./mol | Molecular Formula: | C₈H₉F₂N |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD06761826 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, dry and sealed away from light |
Product Description:
(R)-1-(3,5-Difluorophenyl)ethanamine is primarily utilized in the pharmaceutical industry as a chiral building block for the synthesis of various active pharmaceutical ingredients (APIs). Its enantiomeric purity makes it valuable in the development of drugs that require specific stereochemistry for efficacy, particularly in central nervous system (CNS) therapeutics and enzyme inhibitors. Additionally, it serves as an intermediate in the production of compounds targeting neurological disorders, such as Alzheimer's disease and depression, due to its ability to interact with specific biological receptors. Its fluorinated aromatic ring also enhances metabolic stability, making it a preferred choice in the design of drug candidates with improved pharmacokinetic properties.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | €132.25 |
+
-
|
| 0.250 | 10-20 days | €227.94 |
+
-
|
| 1.000 | 10-20 days | €547.53 |
+
-
|
(R)-1-(3,5-Difluorophenyl)ethanamine
(R)-1-(3,5-Difluorophenyl)ethanamine is primarily utilized in the pharmaceutical industry as a chiral building block for the synthesis of various active pharmaceutical ingredients (APIs). Its enantiomeric purity makes it valuable in the development of drugs that require specific stereochemistry for efficacy, particularly in central nervous system (CNS) therapeutics and enzyme inhibitors. Additionally, it serves as an intermediate in the production of compounds targeting neurological disorders, such as Alzheimer's disease and depression, due to its ability to interact with specific biological receptors. Its fluorinated aromatic ring also enhances metabolic stability, making it a preferred choice in the design of drug candidates with improved pharmacokinetic properties.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :